Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent~* Men or women 18 years of age or older~* Current diagnosis of a recurrence of non-severe, non-complicated CDI~* Subject has a clinical response to standard-of-care CDI antibiotics for the most recent CDI episode~Exclusion Criteria:~* Pregnant, breast-feeding, or considering becoming pregnant during the study~* Prior history, evidence, or diagnosis of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis)~* Any prior diagnosis of diarrhea-predominant irritable bowel syndrome~* Systemic chemotherapy or radiation for the treatment of cancer during the 60 days prior to consent or planned during the 8 weeks following Randomization~* Prior fecal transplant for any condition, regardless of route of administration in the last year or plans to undergo during the study~* Major intra-abdominal surgery within the past 60 days prior to Screening~* History of total colectomy/ileostomy or bariatric surgery~* Admitted to, or expected to be admitted to an intensive care unit for any medical reason. Note: Residents of long term care facilities are eligible study entry~* Planned hospitalization or invasive surgery during the study~* Severe acute illness unrelated to CDI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP101 (Type: EXPERIMENTAL): Full Spectrum Microbiota Capsule
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).